Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
To investigate the clinical characteristics and potential influencing factors of central hypothyroidism in peritoneal dialysis patients treated with roxadustat.
A total of maintenance peritoneal dialysis patients followed up at the Peritoneal Dialysis Center of Department of Nephrology, Peking University International Hospital from June 2020 to December 2024 were enrolled in this study. The levels of thyroid-stimulating hormone (TSH), triiodothyronine (T3), serum thyroxine (T4), free triiodothyronine (FT3), and free thyroxine (FT4) were measured in patients after roxadustat treatment; changes in thyroid hormone levels were re-evaluated after roxadustat discontinuation. The clinical characteristics and potential influencing factors of roxadustat-related central hypothyroidism were analyzed.
Total of 76 peritoneal dialysis patients receiving roxadustat for the treatment of renal anemia were included, among whom 51 were males (67.1%) with a mean age of 58.3±14.6 years. Central hypothyroidism occurred in 12 patients (15.8%), which was characterized by levels of FT4, FT3, T4, and T3 below the lower limit of normal. TSH levels decreased compared with the baseline: 75.0% of these patients had TSH levels below the normal range, with a decrease rate ranging from 18.4% to 88.2%. Symptom questionnaire scores showed that 7 patients (58.3%) had hypothyroidism symptoms of varying degrees, with scores ranging from 1 to 4, and mild symptoms were predominant. Multivariate logistic regression analysis revealed that roxadustat-related central hypothyroidism in peritoneal dialysis patients was not associated with gender, age, baseline hemoglobin (HB) level, or therapeutic dose of roxadustat. However, low baseline plasma albumin (ALB) level might be a risk factor: for each 1 g/L decrease in baseline ALB level, the risk of roxadustat-related central hypothyroidism increased by 17.6%. After discontinuation of roxadustat, TSH levels in all patients returned to the normal range.
When roxadustat is used to treat renal anemia in peritoneal dialysis patients, it carries a risk of central hypothyroidism, and most clinical symptoms are mild. Peritoneal dialysis patients with hypoalbuminemia are at high risk of developing roxadustat-related central hypothyroidism. Therefore, regular monitoring of thyroid function is recommended, and timely discontinuation of roxadustat after the detection of central hypothyroidism can correct thyroid function abnormalities
